This announcement is a separate document:
JCRファーマ：MEDIPALとJCRは、ムコ多糖症IIIB型に対するJR-446の第I/II相試験の日本での臨床試験通知プロセスの完了を発表しました
JCR Pharmaceuticals: MEDIPAL and JCR have announced the completion of the clinical trial notification process for the phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB in Japan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.